October 2026
Largest Diagnostics & Genomics Public Companies in the UK
Benchmark revenue and EBITDA valuation multiples for public comps like
Genus, EDX Medical Group, Abingdon Health, Genedrive and CelLBxHealth.
 | Genus PLC is an animal genetics company focused on improving cattle and pig populations to support sustainable food production. The company operates through two main business units: one providing bovine genetics mainly for dairy and beef cattle, and the other offering porcine genetics for pork production. Genus develops genetically superior breeding animals using scientific techniques. It generates revenue by selling genetics, including semen and embryos, as well as through related services under multi-year royalty agreements. The principal activities of each segment are: (a) Genus PIC porcine sales business, (b) Genus ABS: bovine sales business, and (c) Genus Research and Development: spending on research and development. | $28 | -12% | $1.9B | $2B | 2.2x | 16.3x | ||
| EDX Medical Group PLC is principally engaged in the business of creating health testing solutions and developing biological and digital technologies to improve the detection of diseases and disorders. It develops and provides digital diagnostic products and services for testing in areas including cancer, cardiovascular disease, neurology, and infectious diseases. It operates a molecular biology and diagnostics laboratory in Cambridge, UK, from which it performs research & development, and provides testing and genomic sequencing services. It has two operating segments: Medical goods and Medical services. The majority of revenue is generated from the Medical goods segment. Geographically, all revenue was derived from the United Kingdom. | $0 | -- | $50M | $46M | 105.6x | (6.3x) | ||
| Abingdon Health PLC develops, manufactures, and distributes diagnostic devices and provides regulatory consultancy to diagnostics businesses. It offers integrated lateral flow CRO/CDMO services covering feasibility, manufacturing, packaging, kitting, documentation, and commercial support. Segments include Contract Development (milestone-based third-party work, revenue over time by completion), Contract Manufacturing (development/manufacturing via daily consultancy, revenue at customer control point), Product Sales (AbC-19TM, Pocket Diagnostic, PCRD tests, research antibodies, carriage; point in time), and Regulatory Services (IVD/medical device compliance, revenue over time), with key revenue from Regulatory Services. It operates in the UK, USA/Canada, Europe, and rest of world. | $0 | +84% | $37M | $33M | 3.0x | (8.6x) | ||
| Genedrive PLC is a holding company engaged in the molecular diagnostics business. It operates in one operating segment named Diagnostics which is engaged in the Genedrive Point of need molecular diagnostics platform for the diagnosis of infectious diseases and use in patient stratification (genotyping), pathogen detection, and other indications. Geographically the majority of the revenue is derived from the United Kingdom and also has its presence in Europe, United States of America and Rest of the World. | $0 | +13% | $25M | $25M | 24.8x | (3.5x) | ||
| CelLBxHealth PLC is active in the healthcare sector in the United Kingdom. The Company's principal trading activity is undertaken in relation to the development and commercialization of the Parsortix cell separation system, with deployment in liquid biopsy that is non-invasive cancer diagnostics. It is a medical diagnostic company specializing in the development of pioneering products in cancer diagnostics. Its patented Parsortix technology can potentially treat and diagnose various forms of cancer. The Parsortix system can capture and harvest CTCs from patient blood. Its geographical segments include Europe and North America, of which the majority of its revenue is generated from Europe. | $0 | -- | $12M | $10M | 5.8x | (0.5x) | ||
| Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation. | $2 | -- | $3M | - | - | - | ||
| Median | $0 | +13% | $31M | $33M | 5.8x | (3.5x) |
Financial data powered by FactSet and Morningstar. Valuation multiples as of current fiscal year. For more data, start your free trial here.
Recent Insights
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.